TXG stock forecast, quote, news & analysis
10x Genomics Inc is a life science technology company based in the United States... Show more
10x Genomics (TXG) Stock Analysis: AI Tailwinds and Atera Demand Against a Stretched Valuation
Key Takeaways
- TXG shares pulled back roughly 9.7% over the trailing 30 days, easing from a close near $79.10 to the most recent close near $71.46, after a triple-digit year-to-date advance.
- The stock's sharp earlier rally was driven by enthusiasm for AI-powered biological research and the launch of the Atera spatial biology platform.
- Second-quarter 2026 results beat expectations, and management raised its full-year revenue outlook to a range of $610 million to $630 million.
- Several analysts lifted price targets—Canaccord to $100 and Barclays to $110—but a rich price-to-sales multiple keeps valuation debate front and center.
- Near-term risks include declining instrument revenue, Atera-related transition dynamics, and continued operating losses.
Current Market Snapshot
10x Genomics has been one of the most volatile names in the life science tools sector during 2026. After a powerful run that lifted the stock to its highest levels in years, TXG entered a period of consolidation, giving back a portion of its gains over the trailing month. The pullback reflects profit-taking following a rapid rerating rather than a fundamental deterioration, with sentiment still tied closely to the company's positioning in single-cell and spatial genomics and its exposure to artificial intelligence-driven drug discovery.
The stock now trades well above the levels that prevailed for much of 2025, and the debate has shifted from whether demand can recover to whether current multiples already discount years of execution. Elevated trading volume and wide intraday swings underscore how quickly sentiment can shift around product-transition milestones and analyst target revisions.
10x Genomics (TXG) Business Overview and Competitive Position
10x Genomics develops and sells instruments, consumables, and software used to analyze biological systems at single-cell and spatial resolution. Its flagship Chromium platform anchors the single-cell franchise, while Visium, Xenium, and the newer Atera platform address spatial biology applications. The company's software tools, including the Sentira cloud environment, help researchers analyze increasingly large and complex datasets.
The company competes at the intersection of genomics, life science tools, and computational biology. Its competitive strengths include high data quality, broad multiomic capabilities, and a large installed base spanning academic medical centers, biopharmaceutical companies, and government research institutions. Investors follow the stock closely because its technologies generate the high-resolution biological data increasingly used to train AI models in drug discovery and basic research.
Recent Developments Driving TXG
Second-quarter results, reported in early August 2026, came in ahead of expectations, with revenue of about $151 million and a narrower-than-expected loss. Management raised full-year guidance, citing momentum in consumables and strong early demand for Atera. Gross margin improved to 74% on a comparable basis, and the company ended the quarter with roughly $552 million in cash and marketable securities.
Product momentum has been a central theme. 10x Genomics began commercial shipments of Atera and launched the Sentira cloud analysis platform, both viewed as key to the spatial biology story. Atera has drawn unusually strong early order interest, with booked orders already exceeding the roughly 40 instruments the company expects to ship in 2026.
The company also secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a subsidiary of Qiagen (QGEN), reinforcing its intellectual property position in single-cell analysis. A multi-project research collaboration with Fred Hutchinson Cancer Center extended the company's reach into blood-cancer research, while a series of analyst price-target increases—including Canaccord's move to $100 from $60—highlighted growing confidence in AI-related demand.
Despite these catalysts, shares eased over the trailing month as investors weighed the transition away from legacy spatial products, declining instrument revenue, and a valuation that some analysts describe as already reflecting an optimistic recovery.
Trending AI Robots
For investors seeking a data-driven approach to navigating volatile names like TXG, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches that match different risk profiles and trading styles. The platform presents performance data in a transparent, comparative format designed to support independent research. Traders interested in supplementing their own analysis with automated, quantitative signals may find this resource a useful starting point.
2026 Outlook and What Investors Should Watch
The most important near-term catalyst is the third-quarter earnings report, scheduled for early November, which will clarify the magnitude of the expected sequential revenue dip tied to Atera transition dynamics. Investors will also track Atera shipment progress toward the roughly 40-unit 2026 target and whether fourth-quarter revenue acceleration materializes as guided.
Beyond quarterly results, the key themes are AI-driven demand for biological data, consumable growth durability, and the pace at which Atera and related offerings convert early interest into recurring revenue. Risks include soft academic and government funding, pricing pressure on core instruments, continued operating losses, and the elevated valuation embedded in current share prices. Regulatory and tariff developments, particularly in China, also remain relevant swing factors for the life science tools industry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TXG in upward trend: price rose above 50-day moving average on October 21, 2026
TXG moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 205 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 199 of 232 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 25 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 68 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.930) is normal, around the industry mean (2.923). P/E Ratio (-128.119) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices